Cumberland Pharmaceuticals Inc (CPIX)

  • Get an in-depth profile of Cumberland Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
1.945 -0.055 (-2.75%)
Closed USD Disclaimer

Cumberland Pharmaceuticals Inc Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
85
Equity Type
ORD
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Contact Information
Address
Nashville,37203 United States
Phone
(615) 255-0068
Fax
-
Web
https://www.cumberlandpharma.com
Top Executives
Name
Age
Since
Title
Kenneth John Krogulski 65 2017 Independent Director
A. J. Kazimi 65 1999 Founder, Chairman, President & CEO
Gordon R. Bernard 71 1999 Chairman of Medical Advisory Board & Independent Director
Robert Roberts 82 0000 Member of Medical Advisory Board
Richard C. Dart 0 0000 Member of Medical Advisory Board
Ben deBoisblanc 0 0000 Member of Medical Advisory Board
Neil M. Richie 0 0000 Member of Pharmaceutical Advisory Board
J. William Hix 76 0000 Member of Pharmaceutical Advisory Board
Joseph M. Williams 66 0000 Member of Pharmaceutical Advisory Board
Joseph Carpino 0 0000 Member of Pharmaceutical Advisory Board
Robert A. Anderson 83 0000 Member of Pharmaceutical Advisory Board
David Warrell 0 0000 Member of Medical Advisory Board
Martin S. Brown 59 2022 Director
Timothy Meakin 0 0000 Member of Pharmaceutical Advisory Board
Caroline R. Young 49 2016 Independent Director
Joseph C. Galante 73 2018 Independent Director
James R. Jones 75 2010 Independent Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.